The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease

(2019) Dilan Athauda et al.   JAMA Neurology

Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo

(2018) Shinji Toki et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model

(2018) Liping Zhang et al.   NEUROPEPTIDES

Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease

(2018) Peng Feng et al.   NEUROPHARMACOLOGY

Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models

(2018) Christian Hölscher   NEUROPHARMACOLOGY

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease

(2017) Ziyue Yuan et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation

(2017) Yanwei Li et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease

(2017) Jaishree Jalewa et al.   NEUROPHARMACOLOGY

Cell-Penetrating Peptides: From Basic Research to Clinics

(2017) Giulia Guidotti et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Levodopa and Parkinson Disease—Myths Revisited

(2017) Shen-Yang Lim et al.   JAMA Neurology

Parkinson disease

(2017) Werner Poewe et al.   Nature Reviews Disease Primers

Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells

(2017) Theodora Panagaki et al.   Scientific Reports

Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119

(2016) Helle A. Hassing et al.   BIOCHEMICAL PHARMACOLOGY

Role of the mammalian ATG8/LC3 family in autophagy: differential and compensatory roles in the spatiotemporal regulation of autophagy

(2016) You-Kyung Lee et al.   BMB Reports

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF

(2016) Chenhui Ji et al.   BRAIN RESEARCH

Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells

(2016) Jaishree Jalewa et al.   JOURNAL OF NEUROCHEMISTRY

Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents

(2016) Ian A. Clark et al.   Journal of Neuroinflammation

Pathogenic Upregulation of Glial Lipocalin-2 in the Parkinsonian Dopaminergic System

(2016) B.-W. Kim et al.   JOURNAL OF NEUROSCIENCE

Understanding Dopaminergic Cell Death Pathways in Parkinson Disease

(2016) Patrick P. Michel et al.   NEURON

Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model

(2016) Yanwei Li et al.   NEUROPHARMACOLOGY

A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain

(2016) Lijun Cao et al.   NEUROREPORT

Insulin resistance and Parkinson’s disease: A new target for disease modification?

(2016) D. Athauda et al.   PROGRESS IN NEUROBIOLOGY

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease

(2016) Chenhui Ji et al.   REVIEWS IN THE NEUROSCIENCES

Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model

(2015) YanFang Zhang et al.   BEHAVIOURAL BRAIN RESEARCH

Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes

(2015) M Christensen et al.   INTERNATIONAL JOURNAL OF OBESITY

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

(2015) W. Liu et al.   NEUROSCIENCE

The Interfaces Between Signal Transduction Pathways: IGF-1/mTor, p53 and the Parkinson Disease Pathway

(2015) Arnold J. Levine et al.   Oncotarget

Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases

(2014) Christian Hölscher   BIOCHEMICAL SOCIETY TRANSACTIONS

Involvement of peroxisome proliferator-activated receptor β/δ (PPAR β/δ) in BDNF signaling during aging and in Alzheimer disease: Possible role of 4-hydroxynonenal (4-HNE)

(2014) Elisabetta Benedetti et al.   CELL CYCLE

Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik

(2014) S. Chen et al.   MOLECULAR AND CELLULAR BIOLOGY

The medical treatment of Parkinson disease from James Parkinson to George Cotzias

(2014) Stanley Fahn   MOVEMENT DISORDERS

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Biased and Constitutive Signaling in the CC-chemokine Receptor CCR5 by Manipulating the Interface between Transmembrane Helices 6 and 7

(2013) Anne Steen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Autophagy and apoptosis dysfunction in neurodegenerative disorders

(2013) Saeid Ghavami et al.   PROGRESS IN NEUROBIOLOGY

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain

(2012) Vadivel Parthsarathy et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases

(2012) Mahesh Ramalingam et al.   JOURNAL OF NEURAL TRANSMISSION

Parkinson's Disease: Genetics and Pathogenesis

(2011) Joshua M. Shulman et al.   Annual Review of Pathology-Mechanisms of Disease

Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease

(2011) K. Stahl et al.   BRAIN RESEARCH

The Beclin 1 network regulates autophagy and apoptosis

(2011) R Kang et al.   CELL DEATH AND DIFFERENTIATION

The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinson's disease

(2011) Rui D. S. Prediger et al.   CURRENT PHARMACEUTICAL DESIGN

Lixisenatide for type 2 diabetes mellitus

(2011) Mikkel Christensen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Neurotoxin-based models of Parkinson's disease

(2011) J. Bové et al.   NEUROSCIENCE

Analysis of mutations and the association between polymorphisms in the cerebral dopamine neurotrophic factor (CDNF) gene and Parkinson disease

(2011) Jung-Mi Choi et al.   NEUROSCIENCE LETTERS

PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease

(2009) Nicoletta Schintu et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

(2009) Sehee Kim et al.   JOURNAL OF ENDOCRINOLOGY

Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival

(2009) Kuniyasu Niizuma et al.   JOURNAL OF NEUROCHEMISTRY

Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention

(2009) Malú G. Tansey et al.   NEUROBIOLOGY OF DISEASE

Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease

(2008) J.K. Morris et al.   BRAIN RESEARCH

Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease

(2008) Alexander Harkavyi et al.   Journal of Neuroinflammation